Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study

2020106 citationsJournal Articlebronze Open Access

Authors

Solmaz Sahebjam · Moffitt Cancer Center

Peter Forsyth · University of South Florida

Nam Tran · Moffitt Cancer Center

John A. Arrington · University of South Florida

Robert Macaulay · Moffitt Cancer Center

Arnold B. Etame · University of South Florida

Christine M. Walko ·

Abstract

The combination of HFSRT with pembrolizumab and bevacizumab in patients with recurrent HGG is generally safe and well tolerated. These findings merit further investigation of HFSRT with immunotherapy in HGGs.

Topics & Keywords

Glioma Diagnosis and Treatment Brain Metastases and Treatment Cancer Immunotherapy and Biomarkers

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Neuro-Oncology

Volume 23, Issue 4, pp. 677-686

DOI: 10.1093/neuonc/noaa260

Field-Weighted Citation Impact: 7.84